20-F: Psyence Biomedical Reports Significant Financial Turnaround and Advances Psilocybin Clinical Trials for Palliative Care

Psyence Biomedical Ltd. reported a net profit of $1 million for the fiscal year ended March 31, 2025, a substantial improvement from the prior year's $50.96 million loss, driven by fair value gains on debt conversion and warrant remeasurement, while advancing its Phase IIb psilocybin-assisted psychotherapy study in Australia.

Summary

• Psyence Biomedical Ltd. reported a net profit of $1,011,790 for the fiscal year ended March 31, 2025, a significant improvement from a net loss of $51,159,048 in the prior year.
• This net profit was primarily driven by fair value gains on the conversion of debt into equity ($3,357,628) and warrant liability remeasurement ($694,516), rather than revenue from product sales, as the company currently has no products approved for commercial sale.
• The company's cash and cash equivalents increased substantially to $6,135,166 as of March 31, 2025, from $733,188 as of March 31, 2024, resulting in a positive working capital position of $5,965,908 compared to a negative working capital of $10,978,027 in the prior year.
• Psyence Biomedical successfully regained compliance with all Nasdaq continued listing requirements, as formally notified on June 17, 2025, following a successful compliance hearing on May 29, 2025.
• The company is a clinical-stage biotechnology firm focused on developing natural psilocybin products for psychological trauma and mental health consequences in palliative care.
• Its lead product candidate, PEX010 (a 25mg naturally sourced psilocybin capsule), is being used in a Phase IIb double-blind, randomized, low-dose controlled clinical trial in Australia to assess its efficacy and safety in psilocybin-assisted psychotherapy for Adjustment Disorder (AjD) due to incurable cancer.
• The Phase IIb study, which has received full approval from Australian Human Research Ethics Committees (HRECs), is estimated to commence enrollment in the second half of 2025, with anticipated costs increasing by approximately 5% for 87 patients from the initial $5,575,000 for 75 participants.
• Psyence has secured exclusive IP licensing agreements with Psyence Labs Ltd. for pharmaceutical-grade, nature-derived psilocybin for Substance Use Disorder (SUD), including Alcohol Use Disorder (AUD), and a right of first refusal for ibogaine.
• An Equity Line of Credit (ELOC) agreement for up to $25 million over 24 months was entered into with White Lion Capital, LLC, and a private placement raising $2,000,000 was completed in December 2024.
• Research and development expenses decreased to $342,168 in FY2025 from $954,593 in FY2024, partly due to a temporary slowdown in trial activity during a transition to a new Contract Research Organization (CRO), Southern Star Research.
• The company received an R&D rebate of $879,344 (AUD $1,336,622) from the Australian government in FY2024, but no rebate was received in FY2025 due to lower qualifying expenditures.

Sentiment

Score: 6

Explanation: The company demonstrated a significant financial turnaround from a large loss to a profit, substantially improved its cash position and working capital, and resolved Nasdaq listing compliance issues. It also made operational progress by advancing its lead clinical trial and securing new IP agreements. However, the profit is non-operational, the company remains clinical-stage with no revenue from product sales, faces high industry-specific risks, and has noted internal control weaknesses. The overall sentiment is cautiously positive due to the financial improvements and strategic advancements, but tempered by the inherent risks and early stage of commercialization.

Positives

• Achieved a net profit of $1,011,790 for FY2025, a significant turnaround from a $51,159,048 net loss in FY2024.
• Substantially improved liquidity with cash and cash equivalents increasing to $6,135,166 in FY2025 from $733,188 in FY2024, and a shift to positive working capital of $5,965,908 from a negative $10,978,027.
• Successfully extinguished convertible notes and promissory notes through debt-for-equity exchanges, reducing financial liabilities.
• Regained compliance with all Nasdaq continued listing requirements as of May 29, 2025, mitigating delisting risks.
• Advanced its lead product candidate, PEX010, into a Phase IIb clinical trial in Australia for Adjustment Disorder in palliative care, with enrollment estimated to begin in H2 2025.
• Secured new exclusive IP licensing agreements with Psyence Labs Ltd. for psilocybin in SUD/AUD and a right of first refusal for ibogaine, and with Optimi Health Corp. for other palliative care indications, diversifying its pipeline.
• PEX010 has received regulatory approval for Phase I and II clinical trials in several jurisdictions and has been administered to 132 real-world patients via Health Canada's Special Access Program with no serious adverse events reported.
• Benefits from the Australian Federal Government's Research & Development tax incentive program, providing up to a 43.5% rebate on qualifying R&D expenses, as demonstrated by the $879,344 rebate received in FY2024.
• The FDA's breakthrough therapy designation for psilocybin therapy in severe depressive disorder suggests potential for expedited marketing approval pathways for Psyence's psilocybin-based drug candidates.

Negatives

• The reported net profit of $1,011,790 for FY2025 was primarily driven by non-operating fair value gains on debt conversion and warrant remeasurement, not by revenue from product sales, as the company has no approved products.
• The company has incurred significant operating losses and cash outflows since its inception and anticipates continued losses for the foreseeable future.
• Research and development expenses decreased in FY2025 due to a temporary slowdown in trial activity during a transition to a new CRO, indicating potential operational delays.
• The company has a limited operating history, making predictions about future success or viability less accurate.
• High dependence on third parties for conducting clinical trials (CROs) and for the supply of key materials (Filament for PEX010), introducing supply chain and operational risks.
• The Research IP Agreement with Filament for PEX010, crucial for the Phase IIb study, expires in April 2027, requiring new agreements for Phase III studies and commercialization.
• There is a high rate of failure for product candidates proceeding through clinical trials, and FDA may not accept data from trials conducted outside the U.S. if not under an IND, potentially requiring additional costly trials.
• The psychedelic therapy industry is intensely competitive, with many competitors having greater financial and other resources.
• Negative public opinion and perception of the psychedelic industry, due to its controlled substance status, could adversely impact the company's ability to operate and grow.
• The company's disclosure controls and procedures were deemed 'not effective' as of March 31, 2025, indicating internal control weaknesses.
• The company's status as an emerging growth company and foreign private issuer, while offering exemptions, may make its common shares less attractive to some investors.

Risks

• Investment in biotechnology product development is highly speculative, entailing substantial upfront capital expenditures and significant risk of product candidate failure.
• The company has incurred significant losses since inception and expects to incur significant losses for the foreseeable future, with no products approved for commercial sale or revenue generated to date.
• The company will require substantial additional funding to achieve its business goals, and if unable to obtain it on acceptable terms, may be forced to delay, limit, or terminate product development efforts.
• Operating results are expected to fluctuate significantly due to factors like delays in clinical trials, supply chain interruptions, and ability to obtain additional funding.
• Dependence on current key personnel and the ability to attract and retain qualified employees; loss of key personnel could adversely affect business plan execution.
• Intense competition from major multinational pharmaceutical companies and established biotechnology companies with greater financial and other resources.
• Current and future preclinical and clinical studies will be conducted outside the United States, and the FDA may not accept data from such studies to support NDAs, potentially requiring additional costly and time-consuming trials.
• High rate of failure for product candidates proceeding through clinical trials; positive results from earlier stages are not necessarily predictive of future results.
• Supply chain interruptions, particularly dependence on Filament Health Corp. for PEX010, could delay product development.
• Proprietary information may be lost or security breaches may occur, compromising networks and data.
• Costs associated with compliance with numerous healthcare laws and regulations, and increased enforcement/litigation risks related to the psychedelic therapeutics industry.
• Inability to adequately protect or enforce intellectual property rights, especially for naturally occurring substances like psilocybin, which cannot be patented directly.
• Risk of infringing the intellectual property rights of others, which could prevent or delay product development or increase commercialization costs.
• Difficulties in patient enrollment in clinical trials could delay or adversely affect clinical development activities.
• Inadequate or expensive insurance coverage for potential risks associated with operations.
• Certain significant personnel may allocate time to other businesses, potentially causing conflicts of interest.
• Loss or reduction of research and development incentives from the Australian government could harm operating results.
• Serious adverse events or other safety risks could require abandonment of development, preclude/delay/limit approval, or cause recall/loss of marketing approval.
• The psychedelic therapy industry and market are relatively new and may not continue to exist or grow as anticipated, facing specific marketing challenges due to controlled substance status.
• Negative public opinion and perception of the psychedelic industry could adversely impact operations and growth strategy.
• The psychedelic therapy industry is difficult to quantify, and investors rely on their own estimates of market data accuracy.
• Future sales of securities by existing holders could cause the stock price to decline due to increased shares eligible for resale.
• Failure to meet applicable continued listing requirements could lead to Nasdaq delisting, reducing liquidity and market price.
• The market price and trading volume of common shares may be volatile.
• Warrants exercisable for common shares would increase the number of shares eligible for future resale and result in dilution to shareholders.
• If securities or industry analysts do not publish research, publish inaccurate/unfavorable research, or cease publishing research, share price and trading volume could decline.
• The requirements of being a public company may strain resources, divert management's attention, and affect the ability to attract and retain qualified board members.
• As an emerging growth company and foreign private issuer, reduced SEC reporting requirements may make common shares less attractive to investors.
• Potential classification as a passive foreign investment company (PFIC) could lead to adverse U.S. federal income tax consequences for U.S. taxpayers.
• Difficulties in protecting interests and enforcing rights through U.S. courts due to Canadian incorporation and non-U.S. residency of officers and directors.
• Canadian legislation and the company's Articles of Incorporation contain provisions that may delay or prevent a change in control.
• The company does not expect to pay dividends in the foreseeable future, and shareholders should not rely on an investment in common shares for future dividend income.

Future Outlook

Psyence Biomedical anticipates an increase in R&D expenditure as its new CRO advances the Phase IIb clinical trial, with enrollment estimated to commence in the second half of 2025. The company expects general and administrative costs to remain elevated due to its U.S. public company operations. If the Phase IIb study yields positive results, Psyence believes it may proceed directly to a Phase III trial in the United States, subject to FDA review and IND opening. The estimated launch year for the Proposed End Product in Adjustment Disorder in palliative care patients is 2027. The company plans to expand its targeted indication beyond cancer-related AjD to other types of AjD and secondary indications, including Alcohol Use Disorder and Substance Use Disorder, and is initiating preliminary market research for an AUD study. Psyence will continue to monitor the evolving regulatory landscape in Australia and expects the number of clinics providing psilocybin-assisted psychotherapy to increase significantly once the first psychedelic receives approval for any indication. The company does not expect to pay cash dividends in the foreseeable future, intending to retain funds for business development and growth.

Management Comments

• "The significant increase in the current year reflects the Companys strategic focus on investor awareness and brand positioning following its listing on the NASDAQ in January 2024."
• "The overall decrease in R&D spending is also attributable to the transition to a new contract research organization (CRO) during the year, which resulted in a temporary slowdown in trial activity and associated costs. The Company anticipates that R&D expenditure will increase in future periods as the new CRO advances the clinical trial toward its next development milestones."
• "The significant increase in general and administrative expenses in 2025 reflects the scaling of corporate operations following the Companys NASDAQ listing in January 2024."
• "The Company expects general and administrative costs to remain elevated relative to historical periods as it continues to operate within a U.S. public company environment."
• "The increase reflects the expanded complexity and regulatory requirements of operating as a U.S.-listed public company, and the Company expects to continue incurring elevated levels of professional fees in line with its listing status and strategic initiatives."
• "The Companys current obligations include funding commitments for its Phase IIb palliative care clinical trial. These are expected to be met using existing cash and cash equivalents; however, the Company remains subject to risks, including the potential inability to raise additional funds through equity, debt, or other financing to meet its development plans, operating requirements, and liabilities as they become due."
• "The Company expects that a claw back of the rebate is highly unlikely."
• "We believe that the competitive landscape analysis of other commercial psychedelic-assisted treatments in clinical trials strongly suggests that Psyences clinical asset has a first-mover advantage in both the palliative care and cancer-related AjD market upon approval."
• "As the psilocybin industry continues to evolve, we believe that it is likely that there will be demand for both naturally derived psilocybin formulations as well as synthetic psilocybin (and derivatives) due to both the increasing demand in psilocybin-based research and more importantly, patient accessibility of psilocybin medicines."
• "We believe that the risk of suicide and other AEs will be reduced by thoroughly screening participants for any suicidal tendencies, by excluding patients with histories of suicide attempts and by regular monitoring of suicidal ideation and behavior."
• "Management considers its approach to capital management to be appropriate given the relative size of the Company."

Industry Context

Psyence Biomedical operates within the rapidly growing and changing psychedelic therapy and biotechnology industries. This sector is intensely competitive, featuring major multinational pharmaceutical companies, established biotechnology firms, and research institutions, many of which possess greater financial and R&D resources. The company's focus on natural psilocybin aligns with a burgeoning interest in nature-derived compounds, with psilocybin scientifically noted for its low toxicity and anti-addictive properties, making it a subject of increasing research for various mental health conditions. The FDA's designation of psilocybin therapy as a breakthrough therapy for severe depressive disorder sets a precedent that could expedite regulatory approvals for similar drug candidates, including Psyence's. However, the industry faces challenges related to public perception due to psilocybin's controlled substance status and the nascent stage of the market, which makes market quantification difficult. There is a growing momentum in the U.S. to develop a legal-regulatory framework for therapeutic psychedelics, as evidenced by the Breakthrough Therapies Act and the PACT Caucus, which could positively impact the industry's future.

Comparison to Industry Standards

• The company believes its clinical asset has a 'first-mover advantage' in the palliative care and cancer-related Adjustment Disorder (AjD) market upon approval, based on competitive landscape analysis of other commercial psychedelic-assisted treatments in clinical trials.
• The document references academic studies on psilocybin-assisted psychotherapy (PAP) conducted at institutions like New York School of Medicine and Johns Hopkins University School of Medicine, noting that no serious adverse events (SAEs) were reported in these trials with various psilocybin doses (e.g., 22 mg/70 kg, 30 mg/70 kg, and 0.3 mg/kg).
• It highlights that PAP has demonstrated 'expeditious, substantial, and sustained improvements' in cancer-related anxiety and depression, existential distress, quality of life, and orientation toward death in academic studies, with 60-80% of participants showing clinically significant reductions in depression or anxiety at 6.5-month follow-up in one study of 29 patients, and similar results in another study of 51 patients.
• The document mentions a large-scale study by Compass Pathways with 233 participants on psilocybin efficacy in treatment-resistant depression (TRD), noting that suicidal ideation and intentional self-injury were observed across all treatment groups, which is common in TRD studies, but no mean worsening of suicidal ideation scores was reported.

Management Changes

Corporate Governance

Related Party Transactions

• On January 25, 2024, the company issued an unsecured convertible promissory note (PGI Note) in the principal amount of $1,610,657 to Psyence Group Inc. (PGI) for prior loans. This note was extinguished through debt-for-equity exchanges in September and October 2024, and a make-whole payment in December 2024, involving the issuance of 47,265 common shares.
• On January 25, 2024, the company issued an unsecured convertible promissory note (NCAC Note) in the principal amount of $1,615,501 to the NCAC Sponsor for existing promissory notes. This note was extinguished through debt-for-equity exchanges in September and December 2024, involving the issuance of 52,275 common shares.
• On October 28, 2024, the company acquired 1,000 shares in Psyence Labs Ltd. (PsyLabs) from PGI, the company's parent company, in exchange for 35,594 common shares (including make-whole shares) valued at $722,033.
• Compensation to key management personnel (executive officers and Board of Directors) amounted to $984,697 in short-term benefits for the fiscal year ended March 31, 2025.
• As part of the Business Combination on January 25, 2024, PGI contributed Biomed II to the company in a share-for-share exchange, and the company was previously the therapeutics division of PGI.

Stakeholder Impact

• Shareholders: Experienced significant dilution from share consolidations and equity raises, but also benefited from the company regaining Nasdaq compliance and a substantial improvement in its financial position (though profit is non-operational). Face ongoing risks related to the speculative nature of drug development and potential future dilution.
• Employees and Consultants: Benefit from the company's Equity Incentive Plan, which provides opportunities for equity ownership and compensation, aiming to attract and retain talent.
• Patients: Potential beneficiaries of the company's efforts to develop natural psilocybin products for psychological trauma and mental health conditions, particularly in palliative care, offering new therapeutic options for conditions like Adjustment Disorder, Alcohol Use Disorder, and Substance Use Disorder.
• Suppliers: The company's dependence on third-party manufacturers (e.g., Filament for PEX010) and Contract Research Organizations (CROs) like Southern Star Research creates business opportunities for these partners, but also exposes the company to supply chain risks.
• Creditors: Convertible debt and promissory notes were extinguished through debt-for-equity exchanges, reducing the company's liabilities and improving its balance sheet, which is positive for remaining creditors.

Next Steps

• Commence enrollment for the Phase IIb Study in Australia in the second half of 2025.
• Initiate a Phase III pivotal study program after the completion of the Phase IIb Study, with size and number of trials dependent on Phase IIb results and regulatory advice.
• Continue to evaluate the bridging program into Phase III, which will require regulatory agency approval.
• Expand targeted indication of cancer-related Adjustment Disorder (AjD) to address different types of AjD and other secondary indications.
• Consider further indications, such as Alcohol Use Disorder (AUD) and Substance Use Disorder (SUD), once the AjD program is ongoing.
• Continue preliminary market research and initiate the creation of a steering committee for the AUD study.
• Monitor the evolution of Australia's regulations pertaining to psilocybin and the conduct of clinical trials.
• Anticipate increased R&D expenditure as the new CRO advances the clinical trial toward its next development milestones.
• Expect general and administrative costs to remain elevated as the company continues to operate within a U.S. public company environment.
• Seek additional funds sooner than planned if operating plans change, through public or private equity or debt financings, sales of assets or programs, or strategic collaborations.

Key Dates

Recommendation

Keywords

Psyence Biomedical, Psilocybin, Palliative Care, Biotechnology, Clinical Trials, Adjustment Disorder, Mental Health, Psychedelic Therapy, Drug Development, SEC Filing, Nasdaq, PEX010, Filament Health, Southern Star Research, Alcohol Use Disorder, Substance Use Disorder, Intellectual Property, Pharmaceutical Grade, Natural Psilocybin, Oncology, Anxiety, Depression, PTSD, Grief, Breakthrough Therapy, FDA, TGA, MHRA, EMA, Corporate Governance, Financial Results, Equity Line of Credit